1
|
Perino JH, Patterson M, Momen M, Borisova M, Heslegrave A, Zetterberg H, Gruel J, Binversie EE, Anderson RS, Rylander H, Cameron S, Miranda B, Conidi G, Svaren J, Sample SJ. Neurofilament light chain concentration does not correlate with disease status in Labrador Retrievers affected with idiopathic laryngeal paralysis. Am J Vet Res 2024; 85:ajvr.23.12.0292. [PMID: 38382190 PMCID: PMC11059241 DOI: 10.2460/ajvr.23.12.0292] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2023] [Accepted: 01/25/2024] [Indexed: 02/23/2024]
Abstract
OBJECTIVE The aim of this study was to investigate whether plasma neurofilament light chain (pNfL) concentration was altered in Labrador Retrievers with idiopathic laryngeal paralysis (ILP) compared to a control population. A secondary aim was to investigate relationships between age, height, weight, and body mass index in the populations studied. ANIMALS 123 dogs: 62 purebred Labrador Retrievers with ILP (ILP Cases) and 61 age-matched healthy medium- to large-breed dogs (Controls). METHODS Dogs, recruited from August 1, 2016, to March 1, 2022, were categorized as case or control based on a combination of physical exam, neurologic exam, and history. Blood plasma was collected, and pNfL concentration was measured. pNfL concentrations were compared between ILP Cases and Controls. Covariables including age, height, and weight were collected. Relationships between pNfL and covariables were analyzed within and between groups. In dogs where 2 plasma samples were available from differing time points, pNfL concentrations were measured to evaluate alterations over time. RESULTS No significant difference in pNfL concentration was found between ILP Cases and Control (P = .36). pNfL concentrations had moderate negative correlations with weight and height in the Control group; other variables did not correlate with pNfL concentrations in ILP Case or Control groups. pNfL concentrations do not correlate with ILP disease status or duration in Labrador Retrievers. CLINICAL RELEVANCE There is no evidence that pNfL levels are altered due to ILP disease duration or progression when compared with healthy controls. When evaluating pNfL concentrations in the dog, weight and height should be considered.
Collapse
Affiliation(s)
- Jacquelyn H. Perino
- Comparative Genetic Research Laboratory, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI
| | - Margaret Patterson
- Comparative Genetic Research Laboratory, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI
| | - Mehdi Momen
- Comparative Genetic Research Laboratory, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI
| | - Mina Borisova
- Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK
- UK Dementia Research Institute, University College of London, London, UK
| | - Amanda Heslegrave
- Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK
- UK Dementia Research Institute, University College of London, London, UK
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden
- Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden
| | - Henrik Zetterberg
- Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK
- UK Dementia Research Institute, University College of London, London, UK
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden
- Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden
| | - Jordan Gruel
- Comparative Genetic Research Laboratory, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI
| | - Emily E. Binversie
- Comparative Genetic Research Laboratory, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI
| | - Ryan S. Anderson
- Comparative Genetic Research Laboratory, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI
| | - Helena Rylander
- Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI
| | - Starr Cameron
- Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI
| | - Benjamin Miranda
- Comparative Genetic Research Laboratory, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI
| | - Gabi Conidi
- Comparative Genetic Research Laboratory, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI
| | - John Svaren
- Department of Comparative Biosciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI
| | - Susannah J. Sample
- Comparative Genetic Research Laboratory, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI
| |
Collapse
|
2
|
DiPaola E, Cameron S, Rylander H, Zidan N, Hetzel S. Comparison of D-dimer concentration and thromboelastography for diagnosis of cerebrovascular accidents in dogs: A retrospective study. J Vet Intern Med 2024; 38:1083-1091. [PMID: 38328940 PMCID: PMC10937503 DOI: 10.1111/jvim.17000] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2023] [Accepted: 01/19/2024] [Indexed: 02/09/2024] Open
Abstract
BACKGROUND Cerebrovascular accidents (CVAs) in dogs are diagnosed using magnetic resonance imaging (MRI). This modality is sometimes unavailable, and CVAs can resemble other lesions on MRI. D-dimer concentration and thromboelastography (TEG) are utilized in human medicine in addition to diagnostic imaging to support diagnosis of CVAs, but their use in veterinary patients has not been assessed. OBJECTIVE Assess utility of blood D-dimer concentration and TEG in supporting the imaging diagnosis of CVAs in dogs. ANIMALS Sixty-eight client-owned dogs with neurologic signs that had brain MRI and D-dimer concentration or TEG performed. METHODS Multicenter, retrospective study. The incidence of abnormal D-dimer concentration or TEG was compared between patients with MRI evidence of CVA and a control population. Analysis methods included Fisher's exact test or Chi-squared test for association and comparison of independent proportions. RESULTS Neither D-dimer concentration nor TEG was significantly associated with a CVA (P = .38 and .2, respectively). D-dimer testing was performed in a low-risk population and showed low sensitivity (30.8%; 95% confidence interval [CI], 10%-61%) and high specificity (86.4%; 95% CI, 64%-96%) for CVA diagnosis. Thromboelastography was performed in a high-risk population and showed moderate sensitivity (64.3%; 95% CI, 44%-81%) and specificity (66.7%; 95% CI, 24%-94%) for CVA diagnosis. Abnormal D-dimer concentration or TEG were not helpful in differentiating hemorrhagic from ischemic stroke (P = .43 and .41, respectively). CONCLUSIONS Although blood D-dimer concentration or TEG alone are not diagnostic of CVAs in dogs, a positive D-dimer result supports additional testing for CVA.
Collapse
Affiliation(s)
- Elizabeth DiPaola
- Department of Medical SciencesUniversity of Wisconsin‐MadisonMadisonWisconsinUSA
| | - Starr Cameron
- Department of Medical SciencesUniversity of Wisconsin‐MadisonMadisonWisconsinUSA
| | - Helena Rylander
- Department of Medical SciencesUniversity of Wisconsin‐MadisonMadisonWisconsinUSA
| | - Natalia Zidan
- Department of Medical SciencesUniversity of Wisconsin‐MadisonMadisonWisconsinUSA
| | - Scott Hetzel
- Department of Biostatistics and Medical InformaticsUniversity of Wisconsin‐MadisonMadisonWisconsinUSA
| |
Collapse
|
3
|
Djani DM, Liou M, Aravamuthan S, Lau V, Cameron S. A retrospective study of the efficacy of zonisamide in controlling seizures in 57 cats. J Vet Intern Med 2024; 38:1092-1100. [PMID: 38240116 PMCID: PMC10937493 DOI: 10.1111/jvim.16984] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2023] [Accepted: 12/15/2023] [Indexed: 03/16/2024] Open
Abstract
BACKGROUND Evidence-based recommendations for antiepileptic drug selection in cats beyond phenobarbital are limited, and additional studies are needed for cats where seizures remain inadequately controlled by administration of phenobarbital alone or for cats that cannot safely receive phenobarbital. OBJECTIVE To compare seizure frequency in cats before and after oral administration of zonisamide and describe adverse clinical or clinicopathologic effects in this cohort. ANIMALS Fifty-seven cats with a history of seizures. METHODS Multicenter, retrospective study. Median number of seizures per month and number of seizure days per month were compared before and after administration of zonisamide in all cats, a subgroup of cats with idiopathic epilepsy (IE), and a subgroup of cats receiving zonisamide as sole therapy. Clinical and clinicopathologic adverse effect data were also reported. RESULTS A median decrease of 1 (P = .001, 95% confidence interval (CI) [-1.0, -0.5]) seizure per month, and 1 (P = .003, 95% CI [-1.5, -0.2]) seizure days per month was found across all cats after oral administration of zonisamide. The subgroup with IE showed median decreases of 1 (P = .03, 95% CI [-2.0, -0.5]) and 2 (P = .01, 95% CI [-2.5, -1.0]), respectively. The most common clinical adverse effects were sedation (17%), ataxia (11%), hyporexia (17%), and emesis (5%). One cat developed mild nonregenerative anemia, 2 cats developed mild metabolic acidosis, and 6 cats showed mild increases in ALT and ALP. CONCLUSION Zonisamide was well tolerated and efficacious in controlling seizure activity in most cats.
Collapse
Affiliation(s)
- Dylan M. Djani
- School of Veterinary Medicine, Department of Medical SciencesUniversity of Wisconsin—MadisonMadisonWisconsinUSA
| | - Michael Liou
- School of Veterinary Medicine, Department of StatisticsUniversity of Wisconsin—MadisonMadisonWisconsinUSA
| | - Srikanth Aravamuthan
- School of Veterinary Medicine, Department of StatisticsUniversity of Wisconsin—MadisonMadisonWisconsinUSA
| | - Vivian Lau
- SAGE Veterinary CentersRedwood CityCaliforniaUSA
| | - Starr Cameron
- School of Veterinary Medicine, Department of Medical SciencesUniversity of Wisconsin—MadisonMadisonWisconsinUSA
| |
Collapse
|
4
|
Stewart M, Cameron S, Thunert M, Zampiron A, Wainwright D, Nikora V. High-resolution measurements of swordfish skin surface roughness. Bioinspir Biomim 2023; 19:016007. [PMID: 37995345 DOI: 10.1088/1748-3190/ad0f32] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/05/2023] [Accepted: 11/23/2023] [Indexed: 11/25/2023]
Abstract
The three-dimensional morphology of swordfish skin roughness remains poorly understood. Subsequently, its importance to the overall physiology and hydrodynamic performance of the swordfish is yet to be determined. This is at least partly attributable to the inherent difficulty in making the required measurements of these complex biological surfaces. To address this, here two sets of novel high-resolution measurements of swordfish skin, obtained using a modular optical coherence tomography system and a gel-based stereo-profilometer, are reported and compared. Both techniques are shown to provide three-dimensional morphological data at micron-scale resolution. The results indicate that the skin surface is populated with spiny roughness elements, typically elongated in the streamwise direction, in groups of up to six, and in good agreement with previously reported information based on coarser measurements. In addition, our data also provide new information on the spatial distribution and variability of these roughness features. Two approaches, one continuous and another discrete, are used to derive various topographical metrics that characterize the surface texture of the skin. The information provided here can be used to develop statistically representative synthetic models of swordfish skin roughness.
Collapse
Affiliation(s)
- M Stewart
- School of Engineering, University of Aberdeen, Aberdeen, United Kingdom
| | - S Cameron
- School of Engineering, University of Aberdeen, Aberdeen, United Kingdom
| | | | - A Zampiron
- School of Engineering, University of Aberdeen, Aberdeen, United Kingdom
| | - D Wainwright
- Department of Biological Sciences, Purdue University, West Lafayette, IN, United States of America
| | - V Nikora
- School of Engineering, University of Aberdeen, Aberdeen, United Kingdom
| |
Collapse
|
5
|
Cameron S, Grady KM, Kent SP, Sousa MM. Mild to moderate increases in activity are associated with increased seizure incidence in dogs with idiopathic epilepsy receiving anti-epileptic drugs. J Small Anim Pract 2023; 64:611-618. [PMID: 37572005 DOI: 10.1111/jsap.13655] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2022] [Revised: 03/16/2023] [Accepted: 06/29/2023] [Indexed: 08/14/2023]
Abstract
OBJECTIVE Epilepsy is a chronic disorder, and approximately 25% to 30% of dogs with epilepsy are refractory to anti-epileptic drugs. As increased activity has been shown to reduce seizure frequency in people with epilepsy, the goal of this study was to evaluate the relationship between deviation from baseline activity and seizure incidence in dogs with epilepsy. MATERIALS AND METHODS Activity and seizure data were obtained using a canine activity monitoring device and owner observed seizure logs in 53 dogs with idiopathic epilepsy receiving anti-epileptic drugs. Each dog's activity was individually measured, and 14-day baseline averages were calculated. Logistic regression was performed to evaluate how an observed increase in activity, ranging from 0% to 50%, above baseline activity, affects the incidence of a seizure in the following 24 hours. RESULTS A total of 8540 activity days and 365 seizure days were used in the final analysis with an average of 11 seizures per dog (range 0 to 30 seizures). Seizure incidence was significantly more likely when activity was 10%, 20%, or 30% above baseline activity in the 24 hours before the day of a documented seizure [95% confidence interval (1.02 to 1.60), P=0.033; 95% confidence interval (1.08 to 1.80), P=0.010; 95% confidence interval (1.13 to 2.07), P=0.005, respectively]. However, when activity levels were 40% and 50% above baseline, the effect diminished (95% confidence interval (0.74 to 1.70), P=0.532; or 95% confidence interval (0.56 to 1.66), P=0.988, respectively). CLINICAL SIGNIFICANCE Differently than in humans, this study demonstrated that a mild to moderate increase in activity resulted in a higher seizure incidence within 24 hours in dogs with epilepsy.
Collapse
Affiliation(s)
- S Cameron
- Department of Medical Sciences, University of Wisconsin, Madison, WI, USA
| | - K M Grady
- Clinical Sciences, North Carolina State University, Raleigh, NC, USA
| | - S P Kent
- Department of Statistics, University of Wisconsin - Madison, Madison, WI, USA
| | - M M Sousa
- Ocean State Veterinary Specialists, RI, East Greenwich, USA
| |
Collapse
|
6
|
Murray SD, Cameron S, Tolliver SE, Cole CY, Aschenbroich SA. Rapport de cas Ossifying fibroma in the cervical vertebra of a dog. Can Vet J 2023; 64:367-371. [PMID: 37008640 PMCID: PMC10031789] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 04/04/2023]
Abstract
The objective of this study was to describe the clinical signs, neurologic examination findings, diagnostic imaging results, and pathologic diagnosis of ossifying fibroma in the cervical vertebra of a dog. A 3-year-old spayed female Pembroke Welsh corgi dog exhibited severe cervical pain and left-sided postural reaction deficits. Magnetic resonance imaging (MRI) revealed a lobulated contrast enhancing mass associated with the C6 cervical vertebra. Due to the lack of response to pain medications, humane euthanasia was elected, and histopathologic evaluation of the mass revealed a fibro-osseous lesion most consistent with an ossifying fibroma. This neoplasm is most commonly associated with the mandible of young horses and has not been previously reported in vertebrae in veterinary medicine. Key clinical message: This case is the first report of a fibro-osseous lesion most consistent with an ossifying fibroma affecting a vertebra in veterinary medicine.
Collapse
Affiliation(s)
| | - Starr Cameron
- University of Madison - Wisconsin, Madison, Wisconsin, USA
| | | | - Clara Y Cole
- University of Madison - Wisconsin, Madison, Wisconsin, USA
| | | |
Collapse
|
7
|
Grady K, Cameron S, Kent SP, Barnes Heller H, Barry MM. Effect of an intervention of exercise on sleep and seizure frequency in idiopathic epileptic dogs. J Small Anim Pract 2023; 64:59-68. [PMID: 36368312 PMCID: PMC10099787 DOI: 10.1111/jsap.13568] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2021] [Revised: 07/11/2022] [Accepted: 09/06/2022] [Indexed: 11/12/2022]
Abstract
OBJECTIVE The goal of this study was to compare sleep and seizure frequency between epileptic dogs prescribed a 20% activity increase and epileptic dogs not prescribed an activity increase. METHODS Sixty-nine dogs receiving anti-epileptic drug therapy were enrolled in a 6-month prospective, randomised, placebo-controlled clinical trial with an intention-to-treat analysis. A canine activity monitoring device was used to measure activity levels and sleep scores. RESULTS Using an intention-to-treat analysis, the treatment group had an average of 0.381 more seizures per month (95% CI: 0.09 to 0.68) compared with the control group, although the difference in seizure days per month was not statistically significant. In a subgroup analysis of dogs whose activity increased by at least 10%, partial compliers had 0.719 more seizures per month (95% CI: 0.22 to 1.22) and 0.581 seizure days per month (95% CI: 0.001 to 1.16) compared with the control group. Sleep scores increased by 1.2% in the treatment compared with the control group (95% CI: 0.2 to 2.3%). CONCLUSIONS Seizure frequency and sleep score increased slightly, but significantly, in dogs with idiopathic epilepsy prescribed an increase in activity, compared with a control group.
Collapse
Affiliation(s)
- K Grady
- Department of Medical Sciences, University of Wisconsin - Madison, School of Veterinary Medicine, 2015 Linden Drive, Madison, Wisconsin, 53706, USA
| | - S Cameron
- Department of Medical Sciences, University of Wisconsin - Madison, School of Veterinary Medicine, 2015 Linden Drive, Madison, Wisconsin, 53706, USA
| | - S P Kent
- Department of Medical Sciences, University of Wisconsin - Madison, School of Veterinary Medicine, 2015 Linden Drive, Madison, Wisconsin, 53706, USA
| | - H Barnes Heller
- Barnes Veterinary Specialty Service, Madison, Wisconsin, 53716, USA
| | - M M Barry
- Department of Medical Sciences, University of Wisconsin - Madison, School of Veterinary Medicine, 2015 Linden Drive, Madison, Wisconsin, 53706, USA
| |
Collapse
|
8
|
Solari FP, Sherman AH, Blong AE, Cameron S, Walton RA. Diagnosis and successful management of an extradural compressive hematoma secondary to diphacinone poisoning in a dog. J Vet Emerg Crit Care (San Antonio) 2023; 33:101-106. [PMID: 36098050 PMCID: PMC10087660 DOI: 10.1111/vec.13248] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2021] [Revised: 08/30/2021] [Accepted: 09/11/2021] [Indexed: 01/25/2023]
Abstract
OBJECTIVE To describe the successful case management of an extradural hematoma secondary to anticoagulant rodenticide toxicity causing spinal compression and paraplegia. CASE SUMMARY A 3-month-old, female intact, mixed breed dog was presented for a 12-hour history of paraplegia. CBC and biochemistry results were unremarkable, and a coagulation panel revealed prolonged prothrombin time with normal activated partial thromboplastin time. Magnetic resonance imaging revealed an extradural compressive lesion within the vertebral canal extending from T6 to T11, most consistent with an extradural hematoma. Further coagulation testing revealed a coagulopathy caused by vitamin K1 deficiency and confirmed exposure to the anticoagulant rodenticide, diphacinone. The dog was medically managed with fresh frozen plasma, aminocaproic acid, and oral vitamin K1 therapy. A right-sided T6 to T11 hemilaminectomy was later performed for removal of the extradural hematoma and spinal decompression. The dog's neurological status gradually improved postoperatively and, at the time of discharge, was nonambulatory paraparetic with voluntary micturition. Four weeks postoperatively, the dog had normal prothrombin and activated partial thromboplastin times and was nonambulatory paraparetic with strong motor function. NEW OR UNIQUE INFORMATION PROVIDED This is the first reported case of a dog with an extradural hematoma secondary to anticoagulant rodenticide causing spinal cord compression and neurological deficits. Surgical management of this case was successful and resulted in improvement of neurological signs. Extradural hematoma should be considered as a potential location of bleeding in rodenticide toxicity as well as a differential diagnosis in patients with neurological deficits.
Collapse
Affiliation(s)
- Francesca P Solari
- Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Iowa State University, Ames, Iowa, USA
| | - Alec H Sherman
- Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Iowa State University, Ames, Iowa, USA
| | - April E Blong
- Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Iowa State University, Ames, Iowa, USA
| | - Starr Cameron
- Department of Veterinary Medical Sciences, University of Wisconsin-Madison, Madison, Wisconsin, USA
| | - Rebecca A Walton
- Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Iowa State University, Ames, Iowa, USA
| |
Collapse
|
9
|
Lueck LC, Cameron S, Zidan N. Effects of trazodone administration on the neurologic examination in healthy dogs. J Vet Intern Med 2022; 36:2142-2148. [PMID: 36086912 DOI: 10.1111/jvim.16536] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2022] [Accepted: 08/24/2022] [Indexed: 11/30/2022] Open
Abstract
BACKGROUND Trazodone is an anxiolytic used PO to decrease anxiety in dogs. Whether or not trazodone affects the neurologic examination in dogs has not been previously reported. OBJECTIVE Investigate whether trazodone administration is associated with changes in the neurologic examination in healthy dogs. ANIMALS Thirty-two healthy dogs between 1 and 6 years old with no previously diagnosed medical conditions and perceived by their owners as neurologically normal. METHODS Baseline sedation and anxiety assessments and neurologic examination were performed on each dog, followed by trazodone administration (6.25-8.60 mg/kg PO). The sedation and anxiety assessments and neurologic examination were repeated 2.5 hours after trazodone administration. The examinations were performed by a single board-certified veterinary neurologist and were video-recorded. The videos were randomized and reviewed by a different neurologist, blinded to the previous evaluations, who scored the examinations. RESULTS Seven of 32 (22%) dogs had worse scores on their neurologic examination after receiving trazodone, manifesting as new or progressive PR deficits. Although not clinically relevant, 18.7% of the dogs had consciousness levels that changed from bright, alert, responsive to quiet, alert, responsive after trazodone administration. No other changes were observed on neurologic examination. Sedation and anxiety scores were significantly different after trazodone administration compared to before (P < .001 and P < .001, respectively). CONCLUSIONS AND CLINICAL IMPORTANCE Most dogs did not have changes on neurologic examination after trazodone administration. However, approximately 20% of dogs had new or worsening PR deficits after receiving trazodone. Ideally, trazodone should not be given before neurologic examination in dogs.
Collapse
Affiliation(s)
| | - Starr Cameron
- University of Wisconsin-Madison, Madison, Wisconsin, USA
| | - Natalia Zidan
- University of Wisconsin-Madison, Madison, Wisconsin, USA
| |
Collapse
|
10
|
Krenzke LR, Cameron S, Pritchard JC, Webb DB, Guo LT, Shelton GD. Glossitis in an older non-corgi dog: Diagnosis and long-term follow-up. Can Vet J 2022; 63:825-829. [PMID: 35919473 PMCID: PMC9281888] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
A 9-year-old spayed female 18.8 kg mixed breed boxer dog was referred for evaluation of a 7-month history of difficulty swallowing and prehending food, regurgitation, hypersalivation, and an abnormal dorsiflexion of the tongue. Prior to referral, a barium study was performed, which revealed a mildly dilated esophagus. Treatment with sucralfate, cisapride, and prednisone was initiated. Physical examination revealed bilateral, symmetric atrophy of the temporalis muscles, dorsiflexion of the distal aspect of the tongue with concurrent muscle atrophy, and a reduced gag reflex. Electrodiagnostic examinations revealed spontaneous electrical activity in the muscles of mastication and tongue. Biopsies from the right temporalis, tongue, and biceps femoris muscles were collected. An immune-mediated myositis with fibrosis, scattered CD3, CD4, and CD8+ T-lymphocytes, and upregulation of markers for major histocompatibility antigens were observed in the tongue and temporalis muscles. The dog was treated with a tapering course of prednisone over 2 months and cyclosporine long-term. The dog was maintained on cyclosporine alone for > 2 years and clinical signs remained static, although multiple episodes of aspiration pneumonia occurred. Ultimately, euthanasia was performed due to chronic kidney disease with associated anemia, lethargy, and anorexia.
Collapse
Affiliation(s)
- Lucinda R Krenzke
- University of Wisconsin - Madison, School of Veterinary Medicine, Department of Medical Sciences, Madison, Wisconsin, USA (Krenzke, Cameron, Pritchard); Southeast Veterinary Neurology of Boynton Beach, Boynton Beach, Florida, USA (Webb); Comparative Neuromuscular Laboratory, University of California - San Diego, La Jolla, California, USA (Guo, Shelton)
| | - Starr Cameron
- University of Wisconsin - Madison, School of Veterinary Medicine, Department of Medical Sciences, Madison, Wisconsin, USA (Krenzke, Cameron, Pritchard); Southeast Veterinary Neurology of Boynton Beach, Boynton Beach, Florida, USA (Webb); Comparative Neuromuscular Laboratory, University of California - San Diego, La Jolla, California, USA (Guo, Shelton)
| | - Jessica C Pritchard
- University of Wisconsin - Madison, School of Veterinary Medicine, Department of Medical Sciences, Madison, Wisconsin, USA (Krenzke, Cameron, Pritchard); Southeast Veterinary Neurology of Boynton Beach, Boynton Beach, Florida, USA (Webb); Comparative Neuromuscular Laboratory, University of California - San Diego, La Jolla, California, USA (Guo, Shelton)
| | - D Blake Webb
- University of Wisconsin - Madison, School of Veterinary Medicine, Department of Medical Sciences, Madison, Wisconsin, USA (Krenzke, Cameron, Pritchard); Southeast Veterinary Neurology of Boynton Beach, Boynton Beach, Florida, USA (Webb); Comparative Neuromuscular Laboratory, University of California - San Diego, La Jolla, California, USA (Guo, Shelton)
| | - Ling T Guo
- University of Wisconsin - Madison, School of Veterinary Medicine, Department of Medical Sciences, Madison, Wisconsin, USA (Krenzke, Cameron, Pritchard); Southeast Veterinary Neurology of Boynton Beach, Boynton Beach, Florida, USA (Webb); Comparative Neuromuscular Laboratory, University of California - San Diego, La Jolla, California, USA (Guo, Shelton)
| | - G Diane Shelton
- University of Wisconsin - Madison, School of Veterinary Medicine, Department of Medical Sciences, Madison, Wisconsin, USA (Krenzke, Cameron, Pritchard); Southeast Veterinary Neurology of Boynton Beach, Boynton Beach, Florida, USA (Webb); Comparative Neuromuscular Laboratory, University of California - San Diego, La Jolla, California, USA (Guo, Shelton)
| |
Collapse
|
11
|
Rylander H, Djani DM, Cameron S. Case Report: Bordetella bronchiseptica Meningoencephalomyelitis in a Dog. Front Vet Sci 2022; 9:852982. [PMID: 35450135 PMCID: PMC9016330 DOI: 10.3389/fvets.2022.852982] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2022] [Accepted: 02/11/2022] [Indexed: 12/02/2022] Open
Abstract
A 15-month-old male neutered Wirehaired Pointer mixed-breed dog presented with fever and cervical pain. Cerebrospinal fluid (CSF) analysis showed neutrophilic pleocytosis with intracellular bacteria, and culture of CSF grew Bordetella bronchiseptica. The patient became non-ambulatory 3 days after CSF collection. He was treated with low-dose prednisone for 3.5 months and doxycycline for 1 year. Recheck CSF analysis 1 month after diagnosis showed reduction of inflammation and 3 months after diagnosis revealed only increased protein. The patient improved neurologically over several months and was weakly ambulatory 5 months and fully ambulatory 7 months after diagnosis. Whole genome sequencing of the bacterial isolate and a live modified intranasal vaccine similar to the one the dog had been vaccinated with 7 weeks before diagnosis was similar but not an exact match. Bacterial meningitis should be considered, and culture of CSF is recommended, in cases of neutrophilic pleocytosis of CSF.
Collapse
Affiliation(s)
| | - Dylan M Djani
- University of Wisconsin-Madison, Madison, WI, United States
| | - Starr Cameron
- University of Wisconsin-Madison, Madison, WI, United States
| |
Collapse
|
12
|
Smith TK, Cameron S, Trepanier LA. Incidence of hepatopathies in dogs administered zonisamide orally: A retrospective study of 384 cases. J Vet Intern Med 2022; 36:576-579. [PMID: 35238072 PMCID: PMC8965215 DOI: 10.1111/jvim.16398] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2021] [Revised: 02/16/2022] [Accepted: 02/16/2022] [Indexed: 11/30/2022] Open
Abstract
Background Acute hepatopathy secondary to administration of zonisamide has been reported in 2 dogs, but overall incidence of hepatopathy is unknown. Objective To characterize the incidence of hepatopathy in dogs administered zonisamide PO. Animals Three hundred eighty‐four dogs administered zonisamide PO. Methods Multicenter retrospective study. Medical records were searched for dogs prescribed zonisamide PO and which had follow‐up for at least 3 months (acute exposure) and >3 months (chronic exposure). Reported clinical signs, physical examination findings, and serum biochemical panels were reviewed for possible hepatotoxicosis. Serum alanine aminotransferase (ALT) and alkaline phosphatase (ALP) activity and albumin concentration were documented for all available cases. Results Acute clinical hepatopathy was found in 2 of 384 treated dogs (0.52%, 95% confidence interval [CI], 0.06‐1.9) after 13‐16 days of zonisamide treatment. One additional dog had elevated serum ALT activity with no clinical signs. Of these 3 dogs, 2 recovered after administration of zonisamide was stopped, and 1 was euthanized because of liver failure. Of the 117 cases chronically administered zonisamide, 10 had an increase in ALP, 6 had an increase in ALT, and 1 had hypoalbuminemia. No clinical signs of liver disease were noted in dogs chronically treated with zonisamide (median, 20 months; range, 5‐94 months). Conclusions and Clinical Importance Acute, potentially life‐threatening hepatopathy associated with oral administration of zonisamide to dogs is estimated to occur in less than 1% of dogs and was observed in the first 3 weeks of treatment. Subclinical abnormalities in ALT and ALP activity were noted in <10% of dogs during chronic administration of zonisamide, with no clinical signs of liver disease noted.
Collapse
Affiliation(s)
- Tess K Smith
- University of Wisconsin - Madison, Madison, Wisconsin, USA
| | - Starr Cameron
- University of Wisconsin - Madison, Madison, Wisconsin, USA
| | | |
Collapse
|
13
|
Cameron S, Ramakrishnan R, Patel NP. A persistent plaque on the back of the hand. Clin Exp Dermatol 2022; 47:795-798. [PMID: 35014063 DOI: 10.1111/ced.15040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2021] [Revised: 11/03/2021] [Accepted: 11/29/2021] [Indexed: 11/26/2022]
Abstract
We report the case of a 75-year-old woman presenting with acrodermatitis chronica atrophicans affecting the right hand dorsum, developing after an insect bite sustained in Greece. Diagnosis was confirmed by serology, PCR and histopathological findings. The plaque resolved following a 3-week course of oral doxycycline.
Collapse
Affiliation(s)
- S Cameron
- Dermatology, Imperial College Healthcare NHS Trust, London, UK
| | - R Ramakrishnan
- Histopathology, Imperial College Healthcare NHS Trust, London, UK
| | - N P Patel
- Dermatology, Imperial College Healthcare NHS Trust, London, UK
| |
Collapse
|
14
|
Gorey S, McAteer C, Antonenko A, Abrahams E, Cameron S, Egan A, Ero A, Fraser C, Tey ZH, Boochoon L, Koay WJ, Sitram R, Deegan K, Quinn C. 77 INCONTINENCE AND DECONDITIONING IN A NONFRAIL SAMPLE OF INPATIENTS AT A UNIVERSITY TEACHING HOSPITAL. Age Ageing 2021. [DOI: 10.1093/ageing/afab219.77] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/25/2023] Open
Abstract
Abstract
Background
Incontinence occurs in 26% of hospitalised adults1. Deconditioning in hospitalised adults is common and contributes to increased hospital stay2. The #endpjparalysis movement motivates us to reduce harms of hospitalisation older adults.
Methods
We surveyed inpatients to capture the point prevalence of incontinence. We also collected information regarding functional status, continence status and use of continence wear. Local ethical review-board approval was obtained. All participants provided informed consent.
Results
There were 86 responses. Mean age of participants was 71.5 years. 45.4% were female, >95% were admitted from home and were functionally independent. Mean length of stay for respondents was 7.4 days ±12. The median Clinical Frailty Scale, for respondents aged >65 years, was 3, indicating this cohort is not frail.
17 respondents reported incontinence on the day of survey; 8 of these reported that incontinence was a new experience for them since their admission. 24 respondents wore incontinence wear at home, 31 were wearing incontinence wear on the day of survey.
Of 80 respondents who could toilet independently at home, 23 (26%) reported a new dependency to toilet. Of 83 respondents who mobilised independently at home (with or without an aid), 11 reported needing assistance of one-person to walk, 3 needed the assistance of two-people to walk or stand, five people required a hoist, while 3 were bedbound on the day of survey.
Conclusion
We describe increased dependency in mobility, toileting and increased use of continence wear in non-frail hospitalised older adults. Future work is needed to maintain function during admission to hospital.
References
1. Condon, M., et al. (2019). ‘Urinary and Faecal Incontinence: Point Prevalence and Predictors in a University Hospital.’ Int J Environ Res Public Health 16.
2. Guilcher, S., et al. (2021). ‘A qualitative study exploring the lived experiences of deconditioning in hospital in Ontario, Canada.’ BMC Geriatrics 21.
Collapse
Affiliation(s)
- S Gorey
- University Hospital Limerick , Limerick, Ireland
| | - C McAteer
- University Hospital Limerick , Limerick, Ireland
| | - A Antonenko
- University Hospital Limerick , Limerick, Ireland
| | - E Abrahams
- University Hospital Limerick , Limerick, Ireland
| | - S Cameron
- University Hospital Limerick , Limerick, Ireland
| | - A Egan
- University Hospital Limerick , Limerick, Ireland
| | - A Ero
- University Hospital Limerick , Limerick, Ireland
| | - C Fraser
- University Hospital Limerick , Limerick, Ireland
| | - Z H Tey
- University Hospital Limerick , Limerick, Ireland
| | - L Boochoon
- University Hospital Limerick , Limerick, Ireland
| | - W J Koay
- University Hospital Limerick , Limerick, Ireland
| | - R Sitram
- University Hospital Limerick , Limerick, Ireland
| | - K Deegan
- University Hospital Limerick , Limerick, Ireland
| | - C Quinn
- University Hospital Limerick , Limerick, Ireland
| |
Collapse
|
15
|
Mustafa W, O'Byrne R, Okpaje B, Gabr A, Ali B, Mohamed A, Cameron S, Leahy A, Fernandes L, Mannion M, Ryan P, Ryan S, Peters C, Shanahan E, Galvin R, O'Connor M. 233 BISPHOSPHONATES: ANOTHER COMPLEX DRUG TO PRESCRIBE. Age Ageing 2021. [DOI: 10.1093/ageing/afab219.233] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/25/2023] Open
Abstract
Abstract
Background
Bisphosphonates provide effective treatment for osteoporosis. They accumulate a bone reservoir lasting for 3 years and beyond. The 2021 NICE guidelines recommend a medication review and a ‘drug holiday’ after 5 years of oral bisphosphonate therapy for low-fracture risk patients. Continuing treatment for high risk individuals is advised: age=/>75, previous hip or vertebral fracture, one or more fractures during treatment, recent DEXA scan with T score =/<−2.5, and/or current treatment with oral glucocorticoids. This retrospective audit aimed to assess compliance with NICE guidelines in a primary care setting.
Methods
Data were collected using the Health One online medical record system in an urban general practice. Inclusion criteria: all patients =/> 65 years old, prescribed oral bisphosphonate therapy for osteoporosis for >5 years. Exclusion criteria: deceased, did not attend clinic >1 year, patients on bisphosphonate treatment for conditions other than osteoporosis.
Results
137 patients with a history of bisphosphonate therapy were identified. 76 patients were on bisphosphonate treatment for greater than 5 years. Of the 76 patients, 33 were classified as low-fracture risk and appropriately commenced a drug holiday, while 22 correctly remained on bisphosphonates due to a high fracture risk. The remaining 21 patients inappropriately continued therapy without receiving a medication review, repeat DEXA or fracture-risk assessment.
Conclusion
One third of patients on bisphosphonates beyond 5 years were not assessed for a drug holiday. The aim of a bisphosphonate ‘drug holiday’ is to reduce poly-pharmacy and prevent rare but serious long-term adverse events (such as atypical fractures, osteonecrosis of the jaw, gastric cancer and atrial fibrillation). Factors which had an impact on inappropriate prescribing should be assessed. Incorporating computer-based prescribing alerts could support safe prescribing practices.
Collapse
Affiliation(s)
- W Mustafa
- Department of Ageing and Therapeutics, University Hospital Limerick , Limerick, Ireland
| | - R O'Byrne
- Department of Ageing and Therapeutics, University Hospital Limerick , Limerick, Ireland
| | - B Okpaje
- Department of Ageing and Therapeutics, University Hospital Limerick , Limerick, Ireland
| | - A Gabr
- Department of Ageing and Therapeutics, University Hospital Limerick , Limerick, Ireland
| | - B Ali
- Department of Ageing and Therapeutics, University Hospital Limerick , Limerick, Ireland
| | - A Mohamed
- Department of Ageing and Therapeutics, University Hospital Limerick , Limerick, Ireland
| | - S Cameron
- Department of Ageing and Therapeutics, University Hospital Limerick , Limerick, Ireland
| | - A Leahy
- Department of Ageing and Therapeutics, University Hospital Limerick , Limerick, Ireland
| | - L Fernandes
- Department of Ageing and Therapeutics, University Hospital Limerick , Limerick, Ireland
| | - M Mannion
- Department of Ageing and Therapeutics, University Hospital Limerick , Limerick, Ireland
| | - P Ryan
- Department of Ageing and Therapeutics, University Hospital Limerick , Limerick, Ireland
| | - S Ryan
- Department of Ageing and Therapeutics, University Hospital Limerick , Limerick, Ireland
| | - C Peters
- Department of Ageing and Therapeutics, University Hospital Limerick , Limerick, Ireland
| | - E Shanahan
- Department of Ageing and Therapeutics, University Hospital Limerick , Limerick, Ireland
| | - R Galvin
- School of Allied Health , HRI, , Limerick, Ireland
- University of Limerick , HRI, , Limerick, Ireland
| | - M O'Connor
- Department of Ageing and Therapeutics, University Hospital Limerick , Limerick, Ireland
| |
Collapse
|
16
|
Cameron S, Weltman JG, Fletcher DJ. The prognostic value of admission point-of-care testing and modified Glasgow Coma Scale score in dogs and cats with traumatic brain injuries (2007-2010): 212 cases. J Vet Emerg Crit Care (San Antonio) 2021; 32:75-82. [PMID: 34432934 DOI: 10.1111/vec.13108] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2019] [Revised: 04/21/2020] [Accepted: 04/22/2020] [Indexed: 11/29/2022]
Abstract
OBJECTIVE To investigate the association between admission point-of-care parameters and survival to discharge in dogs and cats with traumatic brain injury (TBI). DESIGN Retrospective study 2007-2010. SETTING A rural university teaching hospital and an urban private practice teaching hospital. ANIMALS One hundred thirty-one dogs and 81 cats admitted to the emergency service with evidence of head injury based on history from the owner or physical exam. MEASUREMENTS AND MAIN RESULTS In dogs, nonsurvivors had significantly higher glucose concentrations at admission than survivors (median = 8.49 mmol/L [153 mg/dl] vs 6.83 mmol/L [123 mg/dl], p = 0.039). In cats, there was no significant difference in admission glucose between survivors and nonsurvivors (median = 10.21 mmol/L [184 mg/dl] vs 10.93 mmol/L [197 mg/dl], p = 0.17). Modified Glasgow Coma Scale (MGCS) score was available for 105 of the 131 dogs (80%) and was significantly higher in survivors than in nonsurvivors (median = 16 vs 11, p < 0.0001). MGCS was available for 45 of the 81 cats (56%) and was significantly higher in survivors than in nonsurvivors (median = 17 vs 14, p = 0.0005). The relative prognostic value of the admission point-of-care testing parameters and MGCS were assessed using a stepwise linear regression model, which included admission glucose, pH, base excess, sodium, and MGCS. In dogs, only admission glucose was an independent predictor of survival (odds ratio = 1.027, 95% confidence interval, 1.0042-1.05, p = 0.019). CONCLUSIONS These results suggest that, as in people with TBI, increased blood glucose concentrations may have prognostic significance in dogs with TBI but not in cats. In addition, MGCS score may be predictive of survival in both dogs and cats with TBI.
Collapse
Affiliation(s)
- Starr Cameron
- Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA
| | - Joel G Weltman
- Emergency and Critical Care Department, Animal Medical Center, New York, New York, USA
| | - Daniel J Fletcher
- Department of Clinical Sciences, Cornell University College of Veterinary Medicine, Ithaca, New York, USA
| |
Collapse
|
17
|
Ammer-Herrmenau C, Asendorf T, Beyer G, Buchholz SM, Cameron S, Damm M, Frost F, Henker R, Jaster R, Phillip V, Placzek M, Ratei C, Sirtl S, van den Berg T, Weingarten MJ, Woitalla J, Mayerle J, Ellenrieder V, Neesse A. Study protocol P-MAPS: microbiome as predictor of severity in acute pancreatitis-a prospective multicentre translational study. BMC Gastroenterol 2021; 21:304. [PMID: 34332533 PMCID: PMC8325304 DOI: 10.1186/s12876-021-01885-4] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/13/2021] [Accepted: 07/22/2021] [Indexed: 12/15/2022] Open
Abstract
Background Acute pancreatitis (AP) is an inflammatory disorder that causes a considerable economic health burden. While the overall mortality is low, around 20% of patients have a complicated course of disease resulting in increased morbidity and mortality. There is an emerging body of evidence that the microbiome exerts a crucial impact on the pathophysiology and course of AP. For several decades multiple clinical and laboratory parameters have been evaluated, and complex scoring systems were developed to predict the clinical course of AP upon admission. However, the majority of scoring systems are determined after several days and achieve a sensitivity around 70% for early prediction of severe AP. Thus, continued efforts are required to investigate reliable biomarkers for the early prediction of severity in order to guide early clinical management of AP patients.
Methods We designed a multi-center, prospective clinical-translational study to test whether the orointestinal microbiome may serve as novel early predictor of the course, severity and outcome of patients with AP. We will recruit 400 AP patients and obtain buccal and rectal swabs within 72 h of admission to the hospital. Following DNA extraction, microbiome analysis will be performed using 3rd generation sequencing Oxford Nanopore Technologies (ONT) for 16S rRNA and metagenomic sequencing. Alpha- and beta-diversity will be determined and correlated to the revised Atlanta classification and additional clinical outcome parameters such as the length of hospital stay, number and type of complications, number of interventions and 30-day mortality. Discussion If AP patients show a distinct orointestinal microbiome dependent on the severity and course of the disease, microbiome sequencing could rapidly be implemented in the early clinical management of AP patients in the future. Trial registration: ClinicalTrials.gov Identifier: NCT04777812
Collapse
Affiliation(s)
- C Ammer-Herrmenau
- Department of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center, Robert-Kochsstraße 40, 37075, Göttingen, Germany
| | - T Asendorf
- Department of Medical Statistics, University Medical Center, Göttingen, Germany
| | - G Beyer
- Department of Medicine II, University Hospital, LMU Munich, Munich, Germany
| | - S M Buchholz
- Department of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center, Robert-Kochsstraße 40, 37075, Göttingen, Germany
| | - S Cameron
- Department of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center, Robert-Kochsstraße 40, 37075, Göttingen, Germany
| | - M Damm
- Department of Medicine I, University Hospital Halle, Halle, Germany
| | - F Frost
- Department of Medicine A, University Medicine Greifswald, Greifswald, Germany
| | - R Henker
- Division of Gastroenterology, Medical Department II, University Hospital of Leipzig, Leipzig, Germany
| | - R Jaster
- Department of Medicine II, University Hospital Rostock, Rostock, Germany
| | - V Phillip
- Department of Medicine II, University Hospital rechts der Isar, Technical University Munich, Munich, Germany
| | - M Placzek
- Department of Medical Statistics, University Medical Center, Göttingen, Germany
| | - C Ratei
- Department of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center, Robert-Kochsstraße 40, 37075, Göttingen, Germany
| | - S Sirtl
- Department of Medicine II, University Hospital, LMU Munich, Munich, Germany
| | - T van den Berg
- Department of Medical Bioinformatics, University Medical Center, Göttingen, Germany
| | - M J Weingarten
- Department of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center, Robert-Kochsstraße 40, 37075, Göttingen, Germany
| | - J Woitalla
- Department of Medicine II, University Hospital Rostock, Rostock, Germany
| | - J Mayerle
- Department of Medicine II, University Hospital, LMU Munich, Munich, Germany
| | - V Ellenrieder
- Department of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center, Robert-Kochsstraße 40, 37075, Göttingen, Germany
| | - A Neesse
- Department of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center, Robert-Kochsstraße 40, 37075, Göttingen, Germany.
| |
Collapse
|
18
|
Barry M, Cameron S, Kent S, Barnes-Heller H, Grady K. Daytime and nocturnal activity in treated dogs with idiopathic epilepsy compared to matched unaffected controls. J Vet Intern Med 2021; 35:1826-1833. [PMID: 34223667 PMCID: PMC8295678 DOI: 10.1111/jvim.16205] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2020] [Revised: 06/10/2021] [Accepted: 06/18/2021] [Indexed: 11/28/2022] Open
Abstract
BACKGROUND In dogs, antiepileptic drugs (AED) cause lethargy but quantitative data regarding the effects of AED on activity levels are not available, and little is known about how AEDs affect sleep quality. OBJECTIVE To quantitatively compare activity levels and nocturnal activity in dogs previously diagnosed with idiopathic epilepsy (IE) receiving AEDs compared to age- and breed-matched control dogs. ANIMALS Sixty-two dogs with IE and 310 control dogs. METHODS This is a 3-month prospective parallel observational study. An activity monitoring device for dogs was used to measure daily activity levels and sleep scores in all dogs. RESULTS Dogs with IE treated with AEDs had an 18% average lower baseline activity level compared to control dogs (P = .005; point estimate = 0.82, 95% confidence interval [CI], 0.75-0.90). The combination of phenobarbital and potassium bromide (KBr) was associated with an average 28% decrease in activity in dogs with IE compared to control dogs (P = .03; point estimate = 0.72; CI, 0.62-0.82). Mean sleep scores were not significantly different in dogs with IE receiving AEDs compared to control dogs (P = .43). However, higher dosages of KBr were associated with lower sleep scores (P = .01). CONCLUSIONS Dogs with IE receiving AEDs have lower activity levels, but no difference in sleep scores, compared to controls. The combination of phenobarbital and KBr had the largest decrease in activity between groups. Higher doses of KBr may affect nocturnal activity in epileptic dogs.
Collapse
Affiliation(s)
- Megan Barry
- Department of Medical Sciences, University of Wisconsin-Madison, Madison, Wisconsin, USA
| | - Starr Cameron
- Department of Medical Sciences, University of Wisconsin-Madison, Madison, Wisconsin, USA
| | - Sean Kent
- Department of Statistics, University of Wisconsin-Madison, Madison, Wisconsin, USA
| | | | - Kylie Grady
- Department of Medical Sciences, University of Wisconsin-Madison, Madison, Wisconsin, USA
| |
Collapse
|
19
|
Dasgupta R, Cameron S, Aucott L, Maclennan G, Thomas R, N’dow J, Norrie J, Anson K, Keeley F, Maclennan S, Starr K, Mcclinton S. TISU (Therepeutic Intervention for Stones in the Ureter): ESWL versus Ureteroscopy, a multicentre RCT. Eur Urol 2021. [DOI: 10.1016/s0302-2838(21)00660-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
20
|
Shathur A, Patel B, Pitiyage G, Cameron S, Hyde N. Odontogenic keratocyst located in the retromolar trigone. Oral Surg Oral Med Oral Pathol Oral Radiol 2021; 132:e82-e85. [PMID: 34020916 DOI: 10.1016/j.oooo.2021.02.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2020] [Revised: 02/16/2021] [Accepted: 02/17/2021] [Indexed: 10/22/2022]
Abstract
Odontogenic keratocysts (OKCs) are a commonly occurring, benign cystic intraosseous lesion thought to arise from the cell rests of the dental lamina. Most instances of OKC are commonly found in the posterior aspect of the mandible. In rare instances, there have been reported cases of OKCs arising in the peripheral gingiva, but these cases are few and far between. Rarer still are the few documented cases of OKCs arising in other soft tissues of the mouth. There are many divided opinions on the diagnosis of these lesions and whether they are truly odontogenic in origin, given their location when they are enucleated from a soft tissue area. To the best of our knowledge, we present the first reported case of a patient with a peripheral OKC located in the retromolar trigone. We discuss this unique case and review the current literature on peripheral OKCs.
Collapse
Affiliation(s)
- Adam Shathur
- Oral and Maxillofacial Surgery, St. George's Hospital, London, United Kingdom.
| | - B Patel
- Oral and Maxillofacial Surgery, St. George's Hospital, London, United Kingdom
| | - G Pitiyage
- St. George's Hospital, London, United Kingdom
| | - S Cameron
- Oral and Maxillofacial Surgery, St. George's Hospital, London, United Kingdom
| | - N Hyde
- Oral and Maxillofacial Surgery, St. George's Hospital, London, United Kingdom
| |
Collapse
|
21
|
Cameron S, Hoskinson J, Alex CE. MRI and pathological findings in a cat with cranial thoracic vertebral canal stenosis. J Small Anim Pract 2020; 62:502. [PMID: 33094838 DOI: 10.1111/jsap.13256] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2019] [Revised: 10/05/2020] [Accepted: 10/08/2020] [Indexed: 11/29/2022]
Affiliation(s)
- S Cameron
- Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin, 2015 Linden Drive, Madison, WI, 53706, USA
| | - J Hoskinson
- Department of Radiology, Hoskinson, DACVR, LLC, Denver, CO, 80513, USA
| | - C E Alex
- School of Veterinary Medicine, University of California, Davis, CA, 95616, USA
| |
Collapse
|
22
|
Barnard L, Durand A, Blume L, Lee L, Cameron S. Aventriculi associated with holoprosencephaly in a dog. J Vet Intern Med 2020; 34:2682-2686. [PMID: 33009835 PMCID: PMC7694808 DOI: 10.1111/jvim.15907] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2020] [Revised: 08/31/2020] [Accepted: 09/15/2020] [Indexed: 11/30/2022] Open
Abstract
CASE DESCRIPTION A 10-month-old neutered male mixed breed dog was presented for assessment of poorly controlled seizures. CLINICAL FINDINGS Magnetic resonance imaging of the brain disclosed complete absence of the lateral and third ventricles and mesencephalic aqueduct. Postmortem computed tomographic (CT) imaging and positive contrast cisterno-ventriculography confirmed the lack of a contiguous ventricular system. However, histopathology identified the presence of vestigial lateral and third ventricles with hypoplastic choroid plexus, atresia of the third ventricle, and fused thalami, consistent with a diagnosis of lobar holoprosencephaly (HPE). CLINICAL RELEVANCE To our knowledge, this report is the first case of radiographically confirmed aventriculi associated with HPE, a rare congenital malformation previously reported in people, to be described in veterinary medicine.
Collapse
Affiliation(s)
- Laura Barnard
- Canada West Veterinary Specialists, Vancouver, British Columbia, Canada
| | - Alexane Durand
- Department of Clinical Veterinary Sciences, University of Bern, Bern, Switzerland
| | - Lauren Blume
- Veterinary Imaging Solutions LLC, Milton, Vermont, USA
| | - Laura Lee
- Department of Pathological Sciences, University of Madison - Wisconsin, Madison, Wisconsin, USA
| | - Starr Cameron
- Department of Medical Sciences, University of Wisconsin - Madison, Madison, Wisconsin, USA
| |
Collapse
|
23
|
Cameron S, Brown C, Rodgers N, Purba A, MacDonald-Johns R, Jozlowski K, Carrolan V, Pond J, Patel N, Whitehouse J, Rashid R, Nash E. P317 Patient experience and satisfaction with 0.9% saline nasal irrigation (SNI) in a large UK adult cystic fibrosis centre and potential barriers to use. J Cyst Fibros 2020. [DOI: 10.1016/s1569-1993(20)30646-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
24
|
Cameron S, Brown C, Rodgers N, Purba A, MacDonald-Johns R, Jozlowski K, Carrolan V, Pond J, Patel N, Whitehouse J, Rashid R, Nash E. P312 Patient reported use, effects and tolerance of 0.9% saline nasal irrigation (SNI) in a large UK adult cystic fibrosis centre. J Cyst Fibros 2020. [DOI: 10.1016/s1569-1993(20)30641-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
25
|
Cameron S. Follow up after early medical abortion: less is more. BJOG 2019; 126:1545. [PMID: 31519059 DOI: 10.1111/1471-0528.15940] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- S Cameron
- Chalmers Centre, NHS Lothian, University of Edinburgh, Edinburgh, UK
| |
Collapse
|
26
|
Fiala C, Agostini A, Bombas T, Cameron S, Lertxundi R, Lubusky M, Parachini M, Saya L, Trumbic B, Gemzell Danielsson K. Management of pain associated with up-to-9-weeks medical termination of pregnancy (MToP) using mifepristone–misoprostol regimens: expert consensus based on a systematic literature review. J OBSTET GYNAECOL 2019; 40:591-601. [DOI: 10.1080/01443615.2019.1634027] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Affiliation(s)
- C. Fiala
- Gynmed Clinic, Vienna, Austria
- Department of Women’s and Children’s Health, Division of Obstetrics and Gynaecology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden
| | - A. Agostini
- Obstetric and Gynecology Department, La Conception Hospital, Marseille, France
| | - T. Bombas
- Obstetric Service, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
| | - S. Cameron
- Chalmers Centre, NHS Lothian, Edinburgh, Scotland
| | | | - M. Lubusky
- Department of Obstetrics and Gynaecology, Palacky University Hospital, Olomouc, Czech Republic
| | | | - L. Saya
- Altius Pharma CS, Paris, France
| | | | - K. Gemzell Danielsson
- Department of Women’s and Children’s Health, Division of Obstetrics and Gynaecology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden
| |
Collapse
|
27
|
Brown C, Cameron S, Jozlowski K, MacDonald- Johns R, Pond J, Purba A, Rodgers N, Rashid R, Whitehouse J, Nash E. P396 Patient experience and satisfaction with the AIRVO™ 2 humidification system. J Cyst Fibros 2019. [DOI: 10.1016/s1569-1993(19)30688-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
28
|
Ghias M, Shaw F, Cameron S, Soliman Y, Kutner A, Reyes Gil M, Cohen S. 1010 Anemia in hidradenitis suppurativa, hepcidin as a diagnostic tool. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.03.1086] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
29
|
Cameron S, Lopez A, Glabman R, Abrams E, Johnson S, Field C, Gulland FMD, Buckmaster PS. Proportional loss of parvalbumin-immunoreactive synaptic boutons and granule cells from the hippocampus of sea lions with temporal lobe epilepsy. J Comp Neurol 2019; 527:2341-2355. [PMID: 30861128 DOI: 10.1002/cne.24680] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2018] [Revised: 02/18/2019] [Accepted: 03/02/2019] [Indexed: 01/10/2023]
Abstract
One in 26 people develop epilepsy and in these temporal lobe epilepsy (TLE) is common. Many patients display a pattern of neuron loss called hippocampal sclerosis. Seizures usually start in the hippocampus but underlying mechanisms remain unclear. One possibility is insufficient inhibition of dentate granule cells. Normally parvalbumin-immunoreactive (PV) interneurons strongly inhibit granule cells. Humans with TLE display loss of PV interneurons in the dentate gyrus but questions persist. To address this, we evaluated PV interneuron and bouton numbers in California sea lions (Zalophus californianus) that naturally develop TLE after exposure to domoic acid, a neurotoxin that enters the marine food chain during harmful algal blooms. Sclerotic hippocampi were identified by the loss of Nissl-stained hilar neurons. Stereological methods were used to estimate the number of granule cells and PV interneurons per dentate gyrus. Sclerotic hippocampi contained fewer granule cells, fewer PV interneurons, and fewer PV synaptic boutons, and the ratio of granule cells to PV interneurons was higher than in controls. To test whether fewer boutons was attributable to loss versus reduced immunoreactivity, expression of synaptotagmin-2 (syt2) was evaluated. Syt2 is also expressed in boutons of PV interneurons. Sclerotic hippocampi displayed proportional losses of syt2-immunoreactive boutons, PV boutons, and granule cells. There was no significant difference in the average numbers of PV- or syt2-positive boutons per granule cell between control and sclerotic hippocampi. These findings do not address functionality of surviving synapses but suggest reduced granule cell inhibition in TLE is not attributable to anatomical loss of PV boutons.
Collapse
Affiliation(s)
- Starr Cameron
- Department of Comparative Medicine, Stanford University, Stanford, California
| | - Ariana Lopez
- Department of Comparative Medicine, Stanford University, Stanford, California.,College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina
| | - Raisa Glabman
- Department of Comparative Medicine, Stanford University, Stanford, California.,School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
| | - Emily Abrams
- Department of Comparative Medicine, Stanford University, Stanford, California
| | | | - Cara Field
- The Marine Mammal Center, Sausalito, California
| | | | - Paul S Buckmaster
- Department of Comparative Medicine, Stanford University, Stanford, California.,Department of Neurology & Neurological Sciences, Stanford University, Stanford, California
| |
Collapse
|
30
|
Lin CC, Taylor M, Boni V, Brunsvig P, Geater S, Salvagni S, Garrido Lopez P, Özgüroğlu M, Sriuranpong V, Ponce Aix S, Ascierto P, Fasolo A, Sezer A, Kowalski D, Faris J, Cameron S, Mataraza J, Wu H, Antona V, Ochoa de Olza M. Phase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with advanced melanoma or non-small cell lung cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy288.032] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
31
|
Cameron S. The Role of Kampo in Gastrointestinal Oncology. J Acupunct Meridian Stud 2018. [DOI: 10.1016/j.jams.2018.08.102] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
|
32
|
Joint R, Chen ZE, Cameron S. Breast and reproductive cancers in the transgender population: a systematic review. BJOG 2018; 125:1505-1512. [DOI: 10.1111/1471-0528.15258] [Citation(s) in RCA: 49] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/21/2018] [Indexed: 01/02/2023]
Affiliation(s)
- R Joint
- The University of Edinburgh; Edinburgh UK
| | - ZE Chen
- Chalmers Sexual Health Clinic; Edinburgh UK
| | - S Cameron
- Chalmers Sexual Health Clinic; Edinburgh UK
- Obstetrics and Gynaecology; University of Edinburgh; Royal Infirmary of Edinburgh; Edinburgh UK
| |
Collapse
|
33
|
Cameron S. Venous thromboembolism and combined hormonal contraception: what are the implications for prescribing? BJOG 2017; 124:1500. [DOI: 10.1111/1471-0528.14663] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- S Cameron
- Chalmers Sexual and Reproductive Health Service; NHS Lothian; Edinburgh UK
| |
Collapse
|
34
|
Purcell C, Cameron S, Lawton J, Glasier A, Harden J. Self-management of first trimester medical termination of pregnancy: a qualitative study of women's experiences. BJOG 2017; 124:2001-2008. [PMID: 28421651 PMCID: PMC5724679 DOI: 10.1111/1471-0528.14690] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/02/2017] [Indexed: 11/29/2022]
Abstract
OBJECTIVE To explore the experiences of women in Scotland who return home to complete medical termination of pregnancy (TOP) ≤63 days of gestation, after being administered with mifepristone and misoprostol at an NHS TOP clinic. DESIGN Qualitative interview study. SETTING One National Health Service health board (administrative) area in Scotland. POPULATION OR SAMPLE Women in Scotland who had undergone medical TOP ≤63 days, and self-managed passing the pregnancy at home; recruited from three clinics in one NHS health board area between January and July 2014. METHODS In-depth, semi-structured interviews with 44 women in Scotland who had recently undergone TOP ≤63 days of gestation, and who returned home to pass the pregnancy. Data were analysed thematically using an approach informed by the Framework method. MAIN OUTCOME MEASURES Women's experiences of self-management of TOP ≤63 days of gestation. RESULTS Key themes emerging from the analysis related to self-administration of misoprostol in clinic; reasons for choosing home self-management; facilitation of self-management and expectation-setting; experiences of getting home; self-managing and monitoring treatment progress; support for self-management (in person and remotely); and pregnancy self-testing to confirm completion. CONCLUSIONS Participants primarily found self-administration of misoprostol and home self-management to be acceptable and/or preferable, particularly where this was experienced as a decision made jointly with health professionals. The way in which home self-management is presented to women at clinic requires ongoing attention. Women could benefit from the option of home administration of misoprostol. TWEETABLE ABSTRACT Women undergoing medical TOP 63 days found home self-management to be acceptable and/or preferable.
Collapse
Affiliation(s)
- C Purcell
- MRC/CSO Social and Public Health Sciences Unit, University of Glasgow, Glasgow, UK
| | - S Cameron
- Chalmers Centre for Sexual and Reproductive Health (NHS Lothian), Edinburgh, UK
| | - J Lawton
- Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK
| | - A Glasier
- Obstetrics and Gynaecology, Queen's Medical Research Institute, University of Edinburgh, Edinburgh, UK
| | - J Harden
- Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK
| |
Collapse
|
35
|
Cameron S, Eglon G, Hastings L, Straub V, Guglieri M, Lochmüller H, Bushby K, Marini-Bettolo C. An audit on the reasons why patients failed to attend the Newcastle University Trust Hospitals’ Neuromuscular Clinics, at the John Walton Muscular Dystrophy Research Centre, and the actions taken. Neuromuscul Disord 2017. [DOI: 10.1016/s0960-8966(17)30333-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
36
|
Goldberg D, Cameron S, Sharp G, Burns S, Scott G, Molyneaux P, Scoular A, Downie A, Taylor A. Hepatitis C virus among genitourinary clinic attenders in Scotland: unlinked anonymous testing. Int J STD AIDS 2017. [DOI: 10.1177/095646240101200104] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Our objective is to gauge the prevalence of hepatitis C virus (HCV) antibodies among a population at risk of contracting sexually transmitted infections (STIs) and, thus, the efficiency with which the virus is transmitted sexually. The investigators undertook an unlinked anonymous HCV antibody testing study of residual syphilis serology specimens taken from attenders of genitourinary clinics in Glasgow, Edinburgh and Aberdeen during 1996/97. The results were linked to non-identifying risk information. Anti-HCV prevalences among non-injecting heterosexual men and women, and non-injecting homosexual/bisexual males ranged between 0 and 1.2%; the only exception to this was a 7.7% (4/52) prevalence among homosexual/bisexual males in Aberdeen. The overall anti-HCV prevalence for homosexual/bisexual males was 0.6% (4/668), for heterosexual males 0.8% (32/4135), for heterosexual females 0.3% (10/3035) and for injecting drug users 49% (72/148). Only 3 (all female) of the 46 non-injectors who were antibody positive were non-UK nationals or had lived abroad. HCV antibody positive injectors were less likely to have an acute STI and more likely to know their HCV status than non-injectors; no differences in these parameters were found between positive and negative non-injectors on anonymous HCV antibody testing. Our findings are in keeping with the prevailing view that HCV can be acquired through sexual intercourse but, for most people, the probability of this occurring is extremely low. Interventions to prevent the spread of HCV should be targeted mainly at injecting drug user (IDU) populations.
Collapse
Affiliation(s)
- D Goldberg
- Scottish Centre for Infection and Environmental Health, Glasgow
| | - S Cameron
- Regional Virus Laboratory, Gartnavel General Hospital, Glasgow
| | - G Sharp
- Department of Genitourinary Medicine, Southern General Hospital, Glasgow
| | - S Burns
- Regional Virus Laboratory, City Hospital, Edinburgh
| | - G Scott
- Department of Genitourinary Medicine, Royal Infirmary, Edinburgh
| | - P Molyneaux
- University Department of Bacteriology, Foresterhill, Aberdeen
| | - A Scoular
- Department of Genitourinary Medicine, Royal Infirmary, Glasgow
| | - A Downie
- Department of Genitourinary Medicine, Royal Hospital, Aberdeen, UK
| | - A Taylor
- Scottish Centre for Infection and Environmental Health, Glasgow
| |
Collapse
|
37
|
Hansen A, Xiang J, Liu Q, Tong MX, Sun Y, Liu X, Chen K, Cameron S, Hanson-Easey S, Han GS, Weinstein P, Williams C, Bi P. Experts' Perceptions on China's Capacity to Manage Emerging and Re-emerging Zoonotic Diseases in an Era of Climate Change. Zoonoses Public Health 2016; 64:527-536. [PMID: 28009103 DOI: 10.1111/zph.12335] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2016] [Indexed: 11/28/2022]
Abstract
Zoonotic diseases transmitted by arthropods and rodents are a major public health concern in China. However, interventions in recent decades have helped lower the incidence of several diseases despite the country's large, frequently mobile population and socio-economic challenges. Increasing globalization, rapid urbanization and a warming climate now add to the complexity of disease control and prevention and could challenge China's capacity to respond to threats of emerging and re-emerging zoonoses. To investigate this notion, face-to-face interviews were conducted with 30 infectious disease experts in four cities in China. The case study diseases under discussion were malaria, dengue fever and haemorrhagic fever with renal syndrome, all of which may be influenced by changing meteorological conditions. Data were analysed using standard qualitative techniques. The study participants viewed the current disease prevention and control system favourably and were optimistic about China's capacity to manage climate-sensitive diseases in the future. Several recommendations emerged from the data including the need to improve health literacy in the population regarding the transmission of infectious diseases and raising awareness of the health impacts of climate change amongst policymakers and health professionals. Participants thought that research capacity could be strengthened and human resources issues for front-line staff should be addressed. It was considered important that authorities are well prepared in advance for outbreaks such as dengue fever in populous subtropical areas, and a prompt and coordinated response is required when outbreaks occur. Furthermore, health professionals need to remain skilled in the identification of diseases for which incidence is declining, so that re-emerging or emerging trends can be rapidly identified. Recommendations such as these may be useful in formulating adaptation plans and capacity building for the future control and prevention of climate-sensitive zoonotic diseases in China and neighbouring countries.
Collapse
Affiliation(s)
- A Hansen
- School of Public Health, The University of Adelaide, Adelaide, SA, Australia
| | - J Xiang
- School of Public Health, The University of Adelaide, Adelaide, SA, Australia
| | - Q Liu
- State Key Laboratory of Infectious Disease Prevention and Control, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China
| | - M X Tong
- School of Public Health, The University of Adelaide, Adelaide, SA, Australia
| | - Y Sun
- Department of Epidemiology, Anhui Medical University, Hefei, Anhui, China
| | - X Liu
- State Key Laboratory of Infectious Disease Prevention and Control, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China
| | - K Chen
- School of Public Health, The University of Adelaide, Adelaide, SA, Australia
| | - S Cameron
- School of Public Health, The University of Adelaide, Adelaide, SA, Australia
| | - S Hanson-Easey
- School of Public Health, The University of Adelaide, Adelaide, SA, Australia
| | - G-S Han
- Communications and Media Studies, School of Media, Film and Journalism, Monash University, Clayton, Vic., Australia
| | - P Weinstein
- School of Biological Sciences, The University of Adelaide, Adelaide, SA, Australia
| | - C Williams
- School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, SA, Australia
| | - P Bi
- School of Public Health, The University of Adelaide, Adelaide, SA, Australia
| |
Collapse
|
38
|
Abstract
A study was conducted on the content of personal advertisements using data from 259 placements in a national English newspaper. Univariate statistical tests and a multivariate classification analysis confirmed the previous findings in American studies of women seeking financial resources and men offering financial resources and seeking physical attributes. In contrast to previous studies, women are not significantly more likely to describe physical attributes than are men. Univariate statistical tests suggest a new finding of lesser offers of commitment by men.
Collapse
|
39
|
Cameron S, Rishniw M, Miller AD, Sturges B, Dewey CW. Characteristics and Survival of 121 Cats Undergoing Excision of Intracranial Meningiomas (1994-2011). Vet Surg 2015; 44:772-6. [DOI: 10.1111/vsu.12340] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Starr Cameron
- Department of Clinical Sciences; College of Veterinary Medicine; Cornell University; Ithaca New York
| | - Mark Rishniw
- Veterinary Information Network; Davis California
| | - Andrew D. Miller
- Department of Biomedical Sciences; Section of Anatomic Pathology; College of Veterinary Medicine; Cornell University, Ithaca; New York
| | - Beverly Sturges
- Department of Clinical Sciences; College of Veterinary Medicine; University of California Davis; Davis California
| | - Curtis W. Dewey
- Department of Clinical Sciences; College of Veterinary Medicine; Cornell University; Ithaca New York
| |
Collapse
|
40
|
Brown C, Cameron S, Carrolan V, Ahitan B, Phull S, Rashid R, Whitehouse J, Nash E. ePS03.3 Longer term tolerance and likely adherence to TOBI Podhaler in CF adults. J Cyst Fibros 2015. [DOI: 10.1016/s1569-1993(15)30148-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
41
|
Agaimy A, Bauer S, Beham A, Bertolini J, Haller F, Koschny R, Maier J, Montemurro M, Perez D, Schaefer IM, Schildhaus HU, Wurst C, Cameron S. Gastrointestinale Stromatumoren (GIST) – Neues zu Pathologie, Chirurgie und medikamentöser Therapie. Z Gastroenterol 2015; 53:235-43. [DOI: 10.1055/s-0034-1385711] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Affiliation(s)
| | - S. Bauer
- Innere Klinik (Tumorforschung), Universitätsklinik Essen
| | - A. Beham
- Allgemein-Viszeral- und Kinderchirurgie, Universitätsmedizin Göttingen
| | | | | | - R. Koschny
- Medizinische Klinik IV, Universität Heidelberg
| | - J. Maier
- Hämatologie und Hämostaseologie, Universität Leipzig
| | | | - D. Perez
- Allgemein-Viszeral- und Thoraxchirurgie, Universität Hamburg
| | | | | | - C. Wurst
- Allgemein- und Viszeralchirurgie, Universitätsklinikum Jena
| | - S. Cameron
- Gastroenterologie und Endokrinologie, Universitätsmedizin Göttingen
| |
Collapse
|
42
|
Fayeye F, Borrelli P, Esmyot M, Erinle B, Mahran MA, Neale E, Cameron S, Takher P. Rates of subsequent surgery following endometrial ablation among English women with menorrhagia: population-based cohort study. BJOG 2014; 121:1316. [PMID: 25155328 DOI: 10.1111/1471-0528.12863] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/03/2014] [Indexed: 11/28/2022]
Affiliation(s)
- F Fayeye
- Department of Obstetrics and Gynaecology, Bedford Hospital NHS Trust, Bedford, UK
| | | | | | | | | | | | | | | |
Collapse
|
43
|
Rajacich D, Freeman M, Armstrong-Stassen M, Cameron S, Wolfe B. Commuter migration: work environment factors influencing nurses' decisions regarding choice of employment. Nurs Leadersh (Tor Ont) 2014; 27:56-67. [PMID: 25073057 DOI: 10.12927/cjnl.2014.23836] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
Nurse migration is of global concern for every country, and study of migration can provide critical information for managers concerned with nurse recruitment and retention. This mixed-methods research examined factors influencing registered nurses' (RNs') decisions to work in their home country, Canada, or to commute daily to a nursing position in the United States. Measures included nurses' feelings about their work environment conditions, work status congruence (the goodness of fit between employer expectations and their own regarding hours and times worked), professional development opportunities, and their perceptions of organizational support and autonomy (freedom and independence) in the workplace. All work environment variables were significantly higher for nurses working in Michigan. Qualitative results supported these survey findings, providing additional information about nurses' satisfaction. Nurses in our sample were more satisfied with all the work environment factors examined, even when stress from commuting out of country was experienced. The environmental issues examined in this study should be considered by nurse managers concerned with recruitment and retention of nurses.
Collapse
Affiliation(s)
- D Rajacich
- Associate Professor, Faculty of Nursing University of Windsor Windsor, ON
| | - M Freeman
- Assistant Professor, Faculty of Nursing University of Windsor Windsor, ON
| | - M Armstrong-Stassen
- Professor Emeritus, Odette School of Business University of Windsor Windsor, ON
| | - S Cameron
- Professor Emerita, Faculty of Nursing University of Windsor Windsor, ON
| | - B Wolfe
- Visiting Assistant Professor, Psychology St. Lawrence University Canton, NY
| |
Collapse
|
44
|
Bentley RT, Burcham GN, Heng HG, Levine JM, Longshore R, Carrera-Justiz S, Cameron S, Kopf K, Miller MA. A comparison of clinical, magnetic resonance imaging and pathological findings in dogs with gliomatosis cerebri, focusing on cases with minimal magnetic resonance imaging changes(‡). Vet Comp Oncol 2014; 14:318-30. [PMID: 24945683 DOI: 10.1111/vco.12106] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2014] [Revised: 05/28/2014] [Accepted: 05/28/2014] [Indexed: 11/30/2022]
Abstract
The primary study objective was to determine whether clinical examination and magnetic resonance imaging (MRI) can underestimate canine gliomatosis cerebri (GC); we also investigated immunohistochemical features. Seven dogs with GC were studied; four recruited specifically because of minimal MRI changes. Neuroanatomic localization and the distribution of MRI, gross and sub-gross lesions were compared with the actual histological distribution of neoplastic cells. In six cases, clinical examination predicted focal disease and MRI demonstrated a single lesion or appeared normal. Neoplastic cells infiltrated many regions deemed normal by clinical examination and MRI, and were Olig2-positive and glial fibrillary acid protein-negative. Four dogs had concurrent gliomas. GC is a differential diagnosis for dogs with focal neurological deficits and a normal MRI or a focal MRI lesion. Canine GC is probably mainly oligodendrocytic. Type II GC, a solid glioma accompanying diffuse central nervous system neoplastic infiltration, occurs in dogs as in people.
Collapse
Affiliation(s)
- R T Bentley
- Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Purdue University, West Lafayette, IN, USA
| | - G N Burcham
- Department of Comparative Pathobiology, College of Veterinary Medicine, Purdue University, West Lafayette, IN, USA
| | - H G Heng
- Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Purdue University, West Lafayette, IN, USA
| | - J M Levine
- Department of Small Animal Clinical Sciences, College of Veterinary Medicine & Biomedical Sciences, Texas A&M University, College Station, TX, USA
| | - R Longshore
- Gulf Coast Veterinary Neurology and Neurosurgery, Houston, TX, USA
| | | | - S Cameron
- Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY, USA
| | - K Kopf
- Department of Small Animal Clinical Sciences, Virginia-Maryland Regional College of Veterinary Medicine, Virginia Tech, Blacksburg, VA, USA
| | - M A Miller
- Department of Comparative Pathobiology, College of Veterinary Medicine, Purdue University, West Lafayette, IN, USA
| |
Collapse
|
45
|
Palmateer N, Hutchinson S, McAllister G, Munro A, Cameron S, Goldberg D, Taylor A. Risk of transmission associated with sharing drug injecting paraphernalia: analysis of recent hepatitis C virus (HCV) infection using cross-sectional survey data. J Viral Hepat 2014; 21:25-32. [PMID: 24329854 DOI: 10.1111/jvh.12117] [Citation(s) in RCA: 52] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/04/2012] [Accepted: 03/27/2013] [Indexed: 12/23/2022]
Abstract
Sharing injecting paraphernalia (containers, filters and water) poses a risk of transmitting the hepatitis C virus (HCV). The prevalence of, and risk of HCV from, such behaviour has not been extensively reported in Europe. People who inject drugs (PWID) were recruited in cross-sectional surveys from services providing sterile injecting equipment across Scotland between 2008 and 2010. Participants completed a questionnaire and provided a blood spot for anonymous testing. Logistic regression was used to examine the association between recent HCV infection (anti-HCV negative and HCV-RNA positive) and self-reported measures of injecting equipment sharing in the 6 months preceding interview. Twelve per cent of the sample reported sharing needles/syringes, and 40% reported sharing paraphernalia in the previous 6 months. The adjusted odds ratios (AOR) for sharing needles/syringes (+/- paraphernalia), and sharing only paraphernalia in the last 6 months were 6.7 (95% CI 2.6-17.1) and 3.0 (95% CI 1.2-7.5), respectively. Among those who reported not sharing needles/syringes, sharing containers and filters were both significantly associated with recent HCV infection (AOR 3.1, 95% CI 1.3-7.8 and 3.1, 95% CI 1.3-7.5, respectively); sharing water was not. We present the first study to apply a cross-sectional approach to the analysis of the association between sharing paraphernalia and incident HCV infection and demonstrate consistent results with previous longitudinal studies. The prevalence of paraphernalia sharing in our study population is high, representing significant potential for HCV transmission.
Collapse
Affiliation(s)
- N Palmateer
- Blood-borne Viruses and Sexually Transmitted Infections Section, Health Protection Scotland, Glasgow, UK
| | | | | | | | | | | | | |
Collapse
|
46
|
Lluch-Hernández A, Ruiz Simon A, Huang CS, Cortés Castán J, Ruiz-Borrego M, Telli M, Ismail-Khan R, Parton M, Tseng LM, Chen SC, Schmid P, Mayer I, Hurvitz S, García-Estévez L, Atienza R, Wu M, Cameron S, Beck JT, Bardia A. Abstract OT1-4-04: A phase II randomized, open-label, neoadjuvant study of LCL161, an oral antagonist of inhibitor of apoptosis proteins, in combination with paclitaxel in patients with triple-negative breast cancer. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-ot1-4-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Inhibitor of apoptosis proteins (IAPs) negatively regulate cell death through a variety of mechanisms. LCL161 is an oral small-molecule antagonist of IAPs that has demonstrated single-agent activity and synergy with paclitaxel in breast cancer tumor models. In preclinical studies, a gene expression signature has been shown to enrich for response to LCL161. The recommended dose of LCL161 1800 mg once weekly has demonstrated preliminary antitumor activity with paclitaxel in an ongoing Phase Ib study in patients with breast cancer.
Trial design: This is a Phase II, randomized, open-label study of neoadjuvant paclitaxel with or without LCL161 in women with operable, newly diagnosed triple-negative breast cancer (NCT01617668). Key inclusion criteria include women with histologically confirmed diagnosis of triple-negative breast cancer; clinical stages T2, N0–N2, M0; candidates for mastectomy or breast-conserving surgery; ECOG performance status ≤1; known status of the LCL161-predictive gene expression signature (positive and negative gene signature is a stratification factor); and adequate bone marrow and organ function. Key exclusion criteria are: bilateral or inflammatory breast cancer; locally recurrent breast cancer; patients currently receiving systemic therapy for any other malignancy, or having received systemic therapy for a malignancy in the preceding 3 months; impaired gastrointestinal function that may affect the absorption of LCL161; or uncontrolled cardiac disease.
Patients are randomized 1:1 to receive paclitaxel IV (80 mg/m2 weekly) with or without oral LCL161 (1800 mg once weekly) for 12 weeks (corresponding to 4 treatment cycles). Each treatment arm is stratified 1:1 based on gene expression signature status (positive or negative).
Endpoints: The primary endpoint is pathologic complete response (pCR), defined as the absence of invasive disease in the breast after 12 weeks of therapy, analyzed separately in the gene expression signature positive and negative groups. The key secondary endpoint is the pCR rate following treatment with LCL161 and paclitaxel in gene expression signature-positive or -negative tumors. Other secondary endpoints include: pCR rate in breast after 12 weeks of therapy in the full study population, and in patients with gene expression signature-positive and -negative tumors treated with paclitaxel alone; pCR rate in breast, regional nodes and axilla; biomarker evaluation including caspase 3 activation in tumor; safety; and pharmacokinetics of LCL161.
Statistical methods: pCR analysis will be performed according to treatment group and gene expression signature status. An absolute increase of at least 7.5% in pCR rate of the experimental arm over the control arm will be considered as evidence of clinically relevant efficacy.
Target accrual: Approximately 200 patients will be randomized into this study. Recruitment is ongoing across America, Europe, and Asia.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr OT1-4-04.
Collapse
Affiliation(s)
- A Lluch-Hernández
- Hospital Clinico Universitario de Valencia, Valencia, Spain; Instituto Valenciano de Oncologia, Valencia, Spain; National Taiwan University Hospital, Taipei, Taiwan; Vall d'Hebron University Hospital, Barcelona, Spain; Hospital Virgen del Rocio, Sevilla, Spain; Stanford University Medical Center, Stanford, CA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; The Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom; Taipei Veterans General Hospital, Taipei, Taiwan; Chang Gung Memorial Hospital Linkou, Taipei, Taiwan; Royal Sussex County Hospital, Brighton; Vanderbilt University Medical Center, Nashville, TN; University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA; Hospital de Sanchinarro, Madrid, Spain; Novartis Pharmaceuticals Corp., East Hanover, NJ; Novartis Pharmaceuticals Corp., Cambridge, MA; Highlands Oncology Group, Fayetteville, AR; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
| | - A Ruiz Simon
- Hospital Clinico Universitario de Valencia, Valencia, Spain; Instituto Valenciano de Oncologia, Valencia, Spain; National Taiwan University Hospital, Taipei, Taiwan; Vall d'Hebron University Hospital, Barcelona, Spain; Hospital Virgen del Rocio, Sevilla, Spain; Stanford University Medical Center, Stanford, CA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; The Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom; Taipei Veterans General Hospital, Taipei, Taiwan; Chang Gung Memorial Hospital Linkou, Taipei, Taiwan; Royal Sussex County Hospital, Brighton; Vanderbilt University Medical Center, Nashville, TN; University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA; Hospital de Sanchinarro, Madrid, Spain; Novartis Pharmaceuticals Corp., East Hanover, NJ; Novartis Pharmaceuticals Corp., Cambridge, MA; Highlands Oncology Group, Fayetteville, AR; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
| | - C-S Huang
- Hospital Clinico Universitario de Valencia, Valencia, Spain; Instituto Valenciano de Oncologia, Valencia, Spain; National Taiwan University Hospital, Taipei, Taiwan; Vall d'Hebron University Hospital, Barcelona, Spain; Hospital Virgen del Rocio, Sevilla, Spain; Stanford University Medical Center, Stanford, CA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; The Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom; Taipei Veterans General Hospital, Taipei, Taiwan; Chang Gung Memorial Hospital Linkou, Taipei, Taiwan; Royal Sussex County Hospital, Brighton; Vanderbilt University Medical Center, Nashville, TN; University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA; Hospital de Sanchinarro, Madrid, Spain; Novartis Pharmaceuticals Corp., East Hanover, NJ; Novartis Pharmaceuticals Corp., Cambridge, MA; Highlands Oncology Group, Fayetteville, AR; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
| | - J Cortés Castán
- Hospital Clinico Universitario de Valencia, Valencia, Spain; Instituto Valenciano de Oncologia, Valencia, Spain; National Taiwan University Hospital, Taipei, Taiwan; Vall d'Hebron University Hospital, Barcelona, Spain; Hospital Virgen del Rocio, Sevilla, Spain; Stanford University Medical Center, Stanford, CA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; The Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom; Taipei Veterans General Hospital, Taipei, Taiwan; Chang Gung Memorial Hospital Linkou, Taipei, Taiwan; Royal Sussex County Hospital, Brighton; Vanderbilt University Medical Center, Nashville, TN; University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA; Hospital de Sanchinarro, Madrid, Spain; Novartis Pharmaceuticals Corp., East Hanover, NJ; Novartis Pharmaceuticals Corp., Cambridge, MA; Highlands Oncology Group, Fayetteville, AR; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
| | - M Ruiz-Borrego
- Hospital Clinico Universitario de Valencia, Valencia, Spain; Instituto Valenciano de Oncologia, Valencia, Spain; National Taiwan University Hospital, Taipei, Taiwan; Vall d'Hebron University Hospital, Barcelona, Spain; Hospital Virgen del Rocio, Sevilla, Spain; Stanford University Medical Center, Stanford, CA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; The Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom; Taipei Veterans General Hospital, Taipei, Taiwan; Chang Gung Memorial Hospital Linkou, Taipei, Taiwan; Royal Sussex County Hospital, Brighton; Vanderbilt University Medical Center, Nashville, TN; University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA; Hospital de Sanchinarro, Madrid, Spain; Novartis Pharmaceuticals Corp., East Hanover, NJ; Novartis Pharmaceuticals Corp., Cambridge, MA; Highlands Oncology Group, Fayetteville, AR; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
| | - M Telli
- Hospital Clinico Universitario de Valencia, Valencia, Spain; Instituto Valenciano de Oncologia, Valencia, Spain; National Taiwan University Hospital, Taipei, Taiwan; Vall d'Hebron University Hospital, Barcelona, Spain; Hospital Virgen del Rocio, Sevilla, Spain; Stanford University Medical Center, Stanford, CA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; The Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom; Taipei Veterans General Hospital, Taipei, Taiwan; Chang Gung Memorial Hospital Linkou, Taipei, Taiwan; Royal Sussex County Hospital, Brighton; Vanderbilt University Medical Center, Nashville, TN; University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA; Hospital de Sanchinarro, Madrid, Spain; Novartis Pharmaceuticals Corp., East Hanover, NJ; Novartis Pharmaceuticals Corp., Cambridge, MA; Highlands Oncology Group, Fayetteville, AR; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
| | - R Ismail-Khan
- Hospital Clinico Universitario de Valencia, Valencia, Spain; Instituto Valenciano de Oncologia, Valencia, Spain; National Taiwan University Hospital, Taipei, Taiwan; Vall d'Hebron University Hospital, Barcelona, Spain; Hospital Virgen del Rocio, Sevilla, Spain; Stanford University Medical Center, Stanford, CA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; The Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom; Taipei Veterans General Hospital, Taipei, Taiwan; Chang Gung Memorial Hospital Linkou, Taipei, Taiwan; Royal Sussex County Hospital, Brighton; Vanderbilt University Medical Center, Nashville, TN; University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA; Hospital de Sanchinarro, Madrid, Spain; Novartis Pharmaceuticals Corp., East Hanover, NJ; Novartis Pharmaceuticals Corp., Cambridge, MA; Highlands Oncology Group, Fayetteville, AR; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
| | - M Parton
- Hospital Clinico Universitario de Valencia, Valencia, Spain; Instituto Valenciano de Oncologia, Valencia, Spain; National Taiwan University Hospital, Taipei, Taiwan; Vall d'Hebron University Hospital, Barcelona, Spain; Hospital Virgen del Rocio, Sevilla, Spain; Stanford University Medical Center, Stanford, CA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; The Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom; Taipei Veterans General Hospital, Taipei, Taiwan; Chang Gung Memorial Hospital Linkou, Taipei, Taiwan; Royal Sussex County Hospital, Brighton; Vanderbilt University Medical Center, Nashville, TN; University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA; Hospital de Sanchinarro, Madrid, Spain; Novartis Pharmaceuticals Corp., East Hanover, NJ; Novartis Pharmaceuticals Corp., Cambridge, MA; Highlands Oncology Group, Fayetteville, AR; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
| | - L-M Tseng
- Hospital Clinico Universitario de Valencia, Valencia, Spain; Instituto Valenciano de Oncologia, Valencia, Spain; National Taiwan University Hospital, Taipei, Taiwan; Vall d'Hebron University Hospital, Barcelona, Spain; Hospital Virgen del Rocio, Sevilla, Spain; Stanford University Medical Center, Stanford, CA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; The Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom; Taipei Veterans General Hospital, Taipei, Taiwan; Chang Gung Memorial Hospital Linkou, Taipei, Taiwan; Royal Sussex County Hospital, Brighton; Vanderbilt University Medical Center, Nashville, TN; University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA; Hospital de Sanchinarro, Madrid, Spain; Novartis Pharmaceuticals Corp., East Hanover, NJ; Novartis Pharmaceuticals Corp., Cambridge, MA; Highlands Oncology Group, Fayetteville, AR; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
| | - S-C Chen
- Hospital Clinico Universitario de Valencia, Valencia, Spain; Instituto Valenciano de Oncologia, Valencia, Spain; National Taiwan University Hospital, Taipei, Taiwan; Vall d'Hebron University Hospital, Barcelona, Spain; Hospital Virgen del Rocio, Sevilla, Spain; Stanford University Medical Center, Stanford, CA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; The Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom; Taipei Veterans General Hospital, Taipei, Taiwan; Chang Gung Memorial Hospital Linkou, Taipei, Taiwan; Royal Sussex County Hospital, Brighton; Vanderbilt University Medical Center, Nashville, TN; University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA; Hospital de Sanchinarro, Madrid, Spain; Novartis Pharmaceuticals Corp., East Hanover, NJ; Novartis Pharmaceuticals Corp., Cambridge, MA; Highlands Oncology Group, Fayetteville, AR; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
| | - P Schmid
- Hospital Clinico Universitario de Valencia, Valencia, Spain; Instituto Valenciano de Oncologia, Valencia, Spain; National Taiwan University Hospital, Taipei, Taiwan; Vall d'Hebron University Hospital, Barcelona, Spain; Hospital Virgen del Rocio, Sevilla, Spain; Stanford University Medical Center, Stanford, CA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; The Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom; Taipei Veterans General Hospital, Taipei, Taiwan; Chang Gung Memorial Hospital Linkou, Taipei, Taiwan; Royal Sussex County Hospital, Brighton; Vanderbilt University Medical Center, Nashville, TN; University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA; Hospital de Sanchinarro, Madrid, Spain; Novartis Pharmaceuticals Corp., East Hanover, NJ; Novartis Pharmaceuticals Corp., Cambridge, MA; Highlands Oncology Group, Fayetteville, AR; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
| | - I Mayer
- Hospital Clinico Universitario de Valencia, Valencia, Spain; Instituto Valenciano de Oncologia, Valencia, Spain; National Taiwan University Hospital, Taipei, Taiwan; Vall d'Hebron University Hospital, Barcelona, Spain; Hospital Virgen del Rocio, Sevilla, Spain; Stanford University Medical Center, Stanford, CA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; The Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom; Taipei Veterans General Hospital, Taipei, Taiwan; Chang Gung Memorial Hospital Linkou, Taipei, Taiwan; Royal Sussex County Hospital, Brighton; Vanderbilt University Medical Center, Nashville, TN; University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA; Hospital de Sanchinarro, Madrid, Spain; Novartis Pharmaceuticals Corp., East Hanover, NJ; Novartis Pharmaceuticals Corp., Cambridge, MA; Highlands Oncology Group, Fayetteville, AR; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
| | - S Hurvitz
- Hospital Clinico Universitario de Valencia, Valencia, Spain; Instituto Valenciano de Oncologia, Valencia, Spain; National Taiwan University Hospital, Taipei, Taiwan; Vall d'Hebron University Hospital, Barcelona, Spain; Hospital Virgen del Rocio, Sevilla, Spain; Stanford University Medical Center, Stanford, CA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; The Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom; Taipei Veterans General Hospital, Taipei, Taiwan; Chang Gung Memorial Hospital Linkou, Taipei, Taiwan; Royal Sussex County Hospital, Brighton; Vanderbilt University Medical Center, Nashville, TN; University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA; Hospital de Sanchinarro, Madrid, Spain; Novartis Pharmaceuticals Corp., East Hanover, NJ; Novartis Pharmaceuticals Corp., Cambridge, MA; Highlands Oncology Group, Fayetteville, AR; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
| | - L García-Estévez
- Hospital Clinico Universitario de Valencia, Valencia, Spain; Instituto Valenciano de Oncologia, Valencia, Spain; National Taiwan University Hospital, Taipei, Taiwan; Vall d'Hebron University Hospital, Barcelona, Spain; Hospital Virgen del Rocio, Sevilla, Spain; Stanford University Medical Center, Stanford, CA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; The Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom; Taipei Veterans General Hospital, Taipei, Taiwan; Chang Gung Memorial Hospital Linkou, Taipei, Taiwan; Royal Sussex County Hospital, Brighton; Vanderbilt University Medical Center, Nashville, TN; University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA; Hospital de Sanchinarro, Madrid, Spain; Novartis Pharmaceuticals Corp., East Hanover, NJ; Novartis Pharmaceuticals Corp., Cambridge, MA; Highlands Oncology Group, Fayetteville, AR; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
| | - R Atienza
- Hospital Clinico Universitario de Valencia, Valencia, Spain; Instituto Valenciano de Oncologia, Valencia, Spain; National Taiwan University Hospital, Taipei, Taiwan; Vall d'Hebron University Hospital, Barcelona, Spain; Hospital Virgen del Rocio, Sevilla, Spain; Stanford University Medical Center, Stanford, CA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; The Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom; Taipei Veterans General Hospital, Taipei, Taiwan; Chang Gung Memorial Hospital Linkou, Taipei, Taiwan; Royal Sussex County Hospital, Brighton; Vanderbilt University Medical Center, Nashville, TN; University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA; Hospital de Sanchinarro, Madrid, Spain; Novartis Pharmaceuticals Corp., East Hanover, NJ; Novartis Pharmaceuticals Corp., Cambridge, MA; Highlands Oncology Group, Fayetteville, AR; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
| | - M Wu
- Hospital Clinico Universitario de Valencia, Valencia, Spain; Instituto Valenciano de Oncologia, Valencia, Spain; National Taiwan University Hospital, Taipei, Taiwan; Vall d'Hebron University Hospital, Barcelona, Spain; Hospital Virgen del Rocio, Sevilla, Spain; Stanford University Medical Center, Stanford, CA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; The Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom; Taipei Veterans General Hospital, Taipei, Taiwan; Chang Gung Memorial Hospital Linkou, Taipei, Taiwan; Royal Sussex County Hospital, Brighton; Vanderbilt University Medical Center, Nashville, TN; University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA; Hospital de Sanchinarro, Madrid, Spain; Novartis Pharmaceuticals Corp., East Hanover, NJ; Novartis Pharmaceuticals Corp., Cambridge, MA; Highlands Oncology Group, Fayetteville, AR; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
| | - S Cameron
- Hospital Clinico Universitario de Valencia, Valencia, Spain; Instituto Valenciano de Oncologia, Valencia, Spain; National Taiwan University Hospital, Taipei, Taiwan; Vall d'Hebron University Hospital, Barcelona, Spain; Hospital Virgen del Rocio, Sevilla, Spain; Stanford University Medical Center, Stanford, CA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; The Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom; Taipei Veterans General Hospital, Taipei, Taiwan; Chang Gung Memorial Hospital Linkou, Taipei, Taiwan; Royal Sussex County Hospital, Brighton; Vanderbilt University Medical Center, Nashville, TN; University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA; Hospital de Sanchinarro, Madrid, Spain; Novartis Pharmaceuticals Corp., East Hanover, NJ; Novartis Pharmaceuticals Corp., Cambridge, MA; Highlands Oncology Group, Fayetteville, AR; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
| | - JT Beck
- Hospital Clinico Universitario de Valencia, Valencia, Spain; Instituto Valenciano de Oncologia, Valencia, Spain; National Taiwan University Hospital, Taipei, Taiwan; Vall d'Hebron University Hospital, Barcelona, Spain; Hospital Virgen del Rocio, Sevilla, Spain; Stanford University Medical Center, Stanford, CA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; The Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom; Taipei Veterans General Hospital, Taipei, Taiwan; Chang Gung Memorial Hospital Linkou, Taipei, Taiwan; Royal Sussex County Hospital, Brighton; Vanderbilt University Medical Center, Nashville, TN; University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA; Hospital de Sanchinarro, Madrid, Spain; Novartis Pharmaceuticals Corp., East Hanover, NJ; Novartis Pharmaceuticals Corp., Cambridge, MA; Highlands Oncology Group, Fayetteville, AR; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
| | - A Bardia
- Hospital Clinico Universitario de Valencia, Valencia, Spain; Instituto Valenciano de Oncologia, Valencia, Spain; National Taiwan University Hospital, Taipei, Taiwan; Vall d'Hebron University Hospital, Barcelona, Spain; Hospital Virgen del Rocio, Sevilla, Spain; Stanford University Medical Center, Stanford, CA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; The Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom; Taipei Veterans General Hospital, Taipei, Taiwan; Chang Gung Memorial Hospital Linkou, Taipei, Taiwan; Royal Sussex County Hospital, Brighton; Vanderbilt University Medical Center, Nashville, TN; University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA; Hospital de Sanchinarro, Madrid, Spain; Novartis Pharmaceuticals Corp., East Hanover, NJ; Novartis Pharmaceuticals Corp., Cambridge, MA; Highlands Oncology Group, Fayetteville, AR; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
| |
Collapse
|
47
|
Deshpande A, Gunson R, Bradley A, Cameron S. Hepatitis E: the West of Scotland experience. Scott Med J 2013; 58:178-81. [PMID: 23960058 DOI: 10.1177/0036933013496966] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
BACKGROUND AND AIMS Hepatitis E virus is traditionally regarded as a virus of the developing world and is emerging as a leading cause of non-A/B/C hepatitis. We wished to investigate locally acquired transmission of hepatitis E in the West of Scotland and compare our use of traditional serology versus polymerase chain reaction since the introduction of polymerase chain reaction in 2007. METHODS Clinical details provided on specimens of blood positive for hepatitis E virus by serology or polymerase chain reaction were collated and analysed. RESULTS Since 2007, 30 samples were hepatitis E virus-positive by serology or polymerase chain reaction. Polymerase chain reaction positivity was generally associated with positive serology although four samples were polymerase chain reaction-negative and strongly positive by serology. Interestingly, one-quarter of cases were likely to represent endogenous transmission of the infection. CONCLUSIONS Polymerase chain reaction is valuable in reliably diagnosing hepatitis E virus. However, serology is valuable for diagnosing resolved infection. There may be a high level of undiagnosed locally acquired hepatitis E virus in Scotland.
Collapse
Affiliation(s)
- A Deshpande
- Department of Microbiology, Glasgow Royal Infirmary, UK.
| | | | | | | |
Collapse
|
48
|
Bradley-Stewart A, Jolly L, Adamson W, Gunson R, Frew-Gillespie C, Templeton K, Aitken C, Carman W, Cameron S, McSharry C. Cytokine responses in patients with mild or severe influenza A(H1N1)pdm09. J Clin Virol 2013; 58:100-7. [PMID: 23790455 DOI: 10.1016/j.jcv.2013.05.011] [Citation(s) in RCA: 61] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2013] [Revised: 04/08/2013] [Accepted: 05/06/2013] [Indexed: 01/15/2023]
Abstract
BACKGROUND Influenza virus affects millions of people worldwide each year. More severe infection occurs in the elderly, very young and immunocompromised. In 2009, a new variant of swine origin (influenza A(H1N1)pdm09 virus) emerged that produced severe disease in young healthy adults. OBJECTIVES The aim of this study was to determine whether cytokine concentrations are associated with clinical outcome in patients infected influenza A(H1N1)pdm09 virus. STUDY DESIGN Plasma concentration of 32 cytokines and growth factors were measured using a multiplex bead immunoassay and conventional ELISA in four patient groups. Patients with severe and mild influenza A(H1N1)pdm09 virus infection, rhinovirus infection and healthy volunteers were investigated. In addition, serial samples of respiratory secretions from five patients with severe influenza A(H1N1)pdm09 virus infection were examined. RESULTS The majority of cytokines measured were elevated in patients with viral respiratory infections compared to the healthy controls. Concentrations of IL-6, IL-10, IL-15, IP-10, IL-2R, HGF, ST2 and MIG were significantly higher (p<0.05) and EGF significantly lower (p=0.0001) in patients with severe influenza A(H1N1)pdm09 virus infection compared to those with mild influenza A(H1N1)pdm09 virus and rhinovirus infection. CONCLUSIONS A number of cytokines were found to be substantially elevated in patients with severe influenza A(H1N1)pdm09 virus infection. This supports and extends other published work suggesting a role for proinflammatory cytokines in influenza-induced lung pathology. Interestingly, EGF was significantly lower in patients with severe infection suggesting it is actively suppressed. As EGF has a role in role in cell proliferation and tissue repair, it may protect the lung from host or virus mediated damage.
Collapse
Affiliation(s)
- A Bradley-Stewart
- West of Scotland Specialist Virology Centre, Gartnavel General Hospital, 1053 Great Western Road, Glasgow G12 0YN, United Kingdom.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Cameron S. Commentary on "Drospirenone-containing oral contraceptive pills and the risk of venous and arterial thrombosis: a systematic review". BJOG 2013; 120:811. [PMID: 23802311] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Affiliation(s)
- S Cameron
- Chalmers Sexual and Reproductive Health Service, Edinburgh, UK
| |
Collapse
|
50
|
Cameron S. Reviewer's commentary on 'Continuation of pregnancy after first-trimester exposure to mifepristone: an observational prospective study'. BJOG 2013; 120:575. [PMID: 23599962] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Affiliation(s)
- S Cameron
- Chalmers Sexual and Reproductive Health Service, Edinburgh, UK
| |
Collapse
|